ICU SEASTAR MEDICAL HOLDING CORPORATION

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

DENVER, Dec. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will hold a conference call to discuss business progress and updates.

Date/Time:Wednesday, December 11, 4:30 p.m. ET / 1:30 p.m. PT
  
Pre-Registration: Participants can pre-register for the conference call :
  
 Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
  
Dial In:Those who choose not to pre-register can access the live conference call by dialing the following and requesting the SeaStar Medical call:
 866-777-2509 within the U.S.
 412-317-5413 from outside the U.S.
  

The live webcast of the conference call also will be available . A replay of the call will be available for 48 hours beginning two hours after its completion by dialing 877-344-7529 from within the U.S., 855-669-9658 from Canada or 412-317-0088 from outside the U.S., and entering conference ID 3855739. The webcast will also be archived .

About SeaStar Medical

SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on or .

Contact:

Alliance Advisors IR

Jody Cain

(310) 691-7100

# # #



EN
04/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEASTAR MEDICAL HOLDING CORPORATION

 PRESS RELEASE

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE...

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury Independent DSMB reports zero device-related safety issuesSupports potential clinical benefitTrial sample size re-estimated to strengthen statistical power DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the independent Data Safety Monitoring Review Board (DS...

 PRESS RELEASE

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in P...

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children DENVER, Sept. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that preliminary results from the will be presented by SeaStar Medical and its research collaborators at the . The SAVE Registry presentation will highlight the role of in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and ...

 PRESS RELEASE

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global...

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference DENVER, Sept. 04, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its participation in the upcoming HC Wainwright 27th Annual Global Investment Conference. The SeaStar Medical presentation can be viewed on Friday, September 5, 2025, at 7:00 am Eastern Time. The presentation can be accessed by visiting the ...

 PRESS RELEASE

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic S...

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival Study shows approximately 18% savings per hospitalization DENVER, Sept. 02, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today the publication of a health economic analysis estimat...

 PRESS RELEASE

SeaStar Medical Reports Second Quarter 2025 Financial Results and Prov...

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates Business highlights include: Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolledThree new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI)Positive survival results reported from QUELIMMUNE SAVE Surveillance RegistryWebcast call today at 4:30 p.m. Eastern Time DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatm...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch